Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Abstract 4222: N-acetyl-L-cysteine (NAC) sensitizes psammaplin A induced DNA damage in malignant hematologic cells by enhancing HDAC inhibition

Yu Bao, Yumei He, Dan Liu, Ping Gong, Samuel Waxman, Yongkui Jing

Cancer Res (2025) 85 (8_Supplement_1): 4222.

https://doi.org/10.1158/1538-7445.AM2025-4222

Published: 21 April 2025

View articletitled, Abstract 4222: N-acetyl-L-cysteine (NAC) sensitizes psammaplin A induced DNA damage in malignant hematologic cells by enhancing HDAC inhibition

Journal Articles

Abstract 4215: Targeting TNBC with a novel vorinostat conjugate that selectively inhibits and degrades HDAC3 and HDAC6

Ping Gong, Min Huang, Haoling Wang, Xin Li, Linxiang Zhao, Samuel Waxman, Yongkui Jing

Cancer Res (2025) 85 (8_Supplement_1): 4215.

https://doi.org/10.1158/1538-7445.AM2025-4215

Published: 21 April 2025

View articletitled, Abstract 4215: Targeting TNBC with a novel vorinostat conjugate that selectively inhibits and degrades HDAC3 and HDAC6

Journal Articles

Abstract 1829: Brusatol overcomes tyrosine kinase inhibitors resistance in myeloid leukemia cells by inhibiting translation of fast turnover protein cyclin D1 and Mcl-1

Huiming Hua, Ying Yang, Guangfuxin Lin, Jingyi Zhang, Samuel Waxman, Yongkui Jing

Cancer Res (2024) 84 (6_Supplement): 1829.

https://doi.org/10.1158/1538-7445.AM2024-1829

Published: 22 March 2024

View articletitled, Abstract 1829: Brusatol overcomes tyrosine kinase inhibitors resistance in myeloid leukemia cells by inhibiting translation of fast turnover protein cyclin D1 and Mcl-1

Journal Articles

Abstract 4489: Developing dual FLT3/MNK inhibitors to overcome sorafenib resistance in FLT3-ITD AML cells

Linxiang Zhao, Shuwei Zuo, Kun Xing, Xiaoshuang Yue, Huimin Zhang, Jingyi Zhang, Samuel Waxman, Yongkui Jing

Cancer Res (2024) 84 (6_Supplement): 4489.

https://doi.org/10.1158/1538-7445.AM2024-4489

Published: 22 March 2024

View articletitled, Abstract 4489: Developing dual FLT3/MNK inhibitors to overcome sorafenib resistance in FLT3-ITD AML cells

Journal Articles

Abstract 4579: DNMT1 determines the sensitivity of Class I HDAC inhibitor Psammaplin A to induce apoptosis and DNA damage in hematological malignant cells

Yu Bao, Dan Liu, Zi Wu, Yumei He, Ping Gong, Samuel Waxman, Yongkui Jing

Cancer Res (2024) 84 (6_Supplement): 4579.

https://doi.org/10.1158/1538-7445.AM2024-4579

Published: 22 March 2024

View articletitled, Abstract 4579: DNMT1 determines the sensitivity of Class I HDAC inhibitor Psammaplin A to induce apoptosis and DNA damage in hematological malignant cells

Journal Articles

Abstract 5991: Improved venetoclax therapy by a novel conjugate with artemisinin by NOXA-mediated reduction of Mcl-1 and cyclin D1 protein in myeloid leukemia cells

Jingyi Zhang, Zhenwei Zhang, Samuel Waxman, Linxiang Zhao, Yongkui Jing

Cancer Res (2024) 84 (6_Supplement): 5991.

https://doi.org/10.1158/1538-7445.AM2024-5991

Published: 22 March 2024

View articletitled, Abstract 5991: Improved venetoclax therapy by a novel conjugate with artemisinin by NOXA-mediated reduction of Mcl-1 and cyclin D1 protein in myeloid leukemia cells

Journal Articles

Abstract 6055: COOTO-Me (10e) acts as a molecular glue to target NCOR/HDAC3 degradation

Ping Gong, Min Huang, Xin Li, Haoling Wang, Samuel Waxman, Linxiang Zhao, Yongkui Jing

Cancer Res (2024) 84 (6_Supplement): 6055.

https://doi.org/10.1158/1538-7445.AM2024-6055

Published: 22 March 2024

View articletitled, Abstract 6055: COOTO-Me (10e) acts as a molecular glue to target NCOR/HDAC3 degradation

Journal Articles

Abstract 31: Targeted dissociation of PF1 from SIN3A chromatin regulator complex inhibits tumor growth and metastasis in triple-negative breast cancer

Rama Kadamb, Nidhi Bansal, Boris A Leibovitch, Yeon-Jin Kwon, Ming-Ming Zhou, Eduardo Farias, Samuel Waxman

Cancer Res (2018) 78 (13_Supplement): 31.

https://doi.org/10.1158/1538-7445.AM2018-31

Published: 01 July 2018

View articletitled, Abstract 31: Targeted dissociation of PF1 from SIN3A chromatin regulator complex inhibits tumor growth and metastasis in triple-negative breast cancer

Journal Articles

Abstract 2936: Molecular characterization of the immune subclass of hepatocellualr carcinoma

Daniela Sia, Yang Jiao, Iris Martinez, Olga Kuchuk, Carlos Villacorta Martin, Manuel Castro de Moura, Juan Putra, Genis Camprecios, Swan Thung, Samuel Waxman, Vincenzo Mazzaferro, Manel Esteller, Augusto Villanueva, Josep Maria Llovet

Cancer Res (2017) 77 (13_Supplement): 2936.

https://doi.org/10.1158/1538-7445.AM2017-2936

Published: 01 July 2017

View articletitled, Abstract 2936: Molecular characterization of the immune subclass of hepatocellualr carcinoma

Journal Articles

Abstract 2083: Development of novel targeted adjuvant therapy for triple negative breast cancer

Nidhi Bansal, Eduardo Farias, Veronica Gonzalez, Garry Nolan, Samuel Waxman

Cancer Res (2017) 77 (13_Supplement): 2083.

https://doi.org/10.1158/1538-7445.AM2017-2083

Published: 01 July 2017

View articletitled, Abstract 2083: Development of novel targeted adjuvant therapy for triple negative breast cancer

Journal Articles

Abstract 4115: Inhibition of triple negative breast cancer cell invasion by the targeted interference of Sin3A function affecting Wnt and TGFβ signaling

Yeon-Jin Kwon, Boris A. Leibovitch, Nidhi Bansal, Lutecia Pereira, Edgardo V. Ariztia, Kevin Petrie, Arthur Zelent, Ming-Ming Zhou, Eduardo F. Farias, Samuel Waxman

Cancer Res (2016) 76 (14_Supplement): 4115.

https://doi.org/10.1158/1538-7445.AM2016-4115

Published: 15 July 2016

View articletitled, Abstract 4115: Inhibition of triple negative breast cancer cell invasion by the targeted interference of Sin3A function affecting Wnt and TGFβ signaling

Journal Articles

Abstract 1989: Targeting Sin3-Pf1 complex: Novel site-specific epigenetic therapy for triple negative breast cancer

Nidhi Bansal, Joanna Wexler, Yeon-jin Kwon, Elena C. Gil, Boris Leibovitch, Rajal Sharma, Arthur Zelent, Ming-Ming Zhou, Eduardo Farias, Samuel Waxman

Cancer Res (2015) 75 (15_Supplement): 1989.

https://doi.org/10.1158/1538-7445.AM2015-1989

Published: 01 August 2015

View articletitled, Abstract 1989: Targeting Sin3-Pf1 complex: Novel site-specific epigenetic therapy for triple negative breast cancer

Journal Articles

Abstract 3511: Targeted epigenetic reprogramming reverts tumor progression in triple-negative breast cancer models by the activation of retinoic acid receptor alpha

Nidhi Bansal, Almudena Bosch, Boris A. Leibovitch, Keely Pierzchalski, Zhou Ming-Ming, Maureen Kane, Samuel Waxman, Eduardo Farias

Cancer Res (2015) 75 (15_Supplement): 3511.

https://doi.org/10.1158/1538-7445.AM2015-3511

Published: 01 August 2015

View articletitled, Abstract 3511: Targeted epigenetic reprogramming reverts tumor progression in triple-negative breast cancer models by the activation of retinoic acid receptor alpha

Journal Articles

Abstract P1-12-08: Bortezomib enhances the efficacy of fulvestrant by promoting the aggregation of the ER in the cytoplasm

Doris Germain, Kerin Adelson, George Raptis, Samuel Waxman

Cancer Res (2015) 75 (9_Supplement): P1-12-08.

https://doi.org/10.1158/1538-7445.SABCS14-P1-12-08

Published: 01 May 2015

View articletitled, Abstract P1-12-08: Bortezomib enhances the efficacy of fulvestrant by promoting the aggregation of the ER in the cytoplasm

Journal Articles

Abstract S6-03: Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York cancer consortium trial

Cancer Res (2015) 75 (9_Supplement): S6-03.

https://doi.org/10.1158/1538-7445.SABCS14-S6-03

Published: 01 May 2015

View articletitled, Abstract S6-03: Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York cancer consortium trial

Journal Articles

Abstract 799: Diminishing Mcl-1 protein leads to apoptosis of acute myeloid leukemia cells responding to all trans retinoic acid differentiation

Rui Wang, Lijuan Xia, Janice Gabrilove, Samuel Waxman, Yongkui Jing

Cancer Res (2014) 74 (19_Supplement): 799.

https://doi.org/10.1158/1538-7445.AM2014-799

Published: 01 October 2014

View articletitled, Abstract 799: Diminishing Mcl-1 protein leads to apoptosis of acute myeloid leukemia cells responding to all trans retinoic acid differentiation

Journal Articles

Abstract 807: Selamectin and ivermectin are small molecule inhibitors that interfere with Sin3A-PAH2 function and exert anti-tumor activity in triple-negative breast cancer

Yeon-Jin Kwon, Boris A. Leibovitch, Lei Zeng, Mihaly Mezei, Rossitza Christova, Shuai Yang, Rajal Sharma, Edgardo Aritzia, nidhi bansal, Ming-Ming Zhou, Authur Zelent, Eduardo Farias, Samuel Waxman

Cancer Res (2014) 74 (19_Supplement): 807.

https://doi.org/10.1158/1538-7445.AM2014-807

Published: 01 October 2014

View articletitled, Abstract 807: Selamectin and ivermectin are small molecule inhibitors that interfere with Sin3A-PAH2 function and exert anti-tumor activity in triple-negative breast cancer

Journal Articles

Abstract 411: Targeted PF1, JARID1B inhibition induces epigenetic reprogramming in triple negative breast cancer

Rossitza Christova, Kevin Petrie, Nidhi Bansal, Boris Leibovitch, Louise Howell, Veronica Gil, Ming-Ming Zhou, Edgardo Ariztia, Eduardo Farias, Arthur Zelent, Samuel Waxman

Cancer Res (2014) 74 (19_Supplement): 411.

https://doi.org/10.1158/1538-7445.AM2014-411

Published: 01 October 2014

View articletitled, Abstract 411: Targeted PF1, JARID1B inhibition induces epigenetic reprogramming in triple negative breast cancer

Journal Articles

Abstract 1826: Anti-tumorigenic effects by targeted functional disruption of the Sin3 PAH-2 domain

Edgardo V. Ariztia, Tirtha K. Das, Eduardo F. Farias, Boris Leibovitch, Kevin Petrie, Veronica Gil, Arthur Zelent, Ming-Ming Zhou, Ross L. Cagan, Samuel Waxman

Cancer Res (2012) 72 (8_Supplement): 1826.

https://doi.org/10.1158/1538-7445.AM2012-1826

Published: 15 April 2012

View articletitled, Abstract 1826: Anti-tumorigenic effects by targeted functional disruption of the Sin3 PAH-2 domain

Journal Articles

Abstract LB-412: Combining bexarotene with erlotinib in window of opportunity and phase II trials causes lung cancer responses independent of KRAS mutations

Konstantin H. Dragnev, Tian Ma, Jobin Cyrus, Fabrizio Galimberti, Vincent Memoli, Alexander M. Busch, Gregory J. Tsongalis, Marc A. Seltzer, David Johnstone, Cherie P. Erkmen, William Nugent, James R. Rigas, Xi Liu, Sarah J. Freemantle, Jonathan M. Kurie, Samuel Waxman, Ethan Dmitrovsky

Cancer Res (2011) 71 (8_Supplement): LB-412.

https://doi.org/10.1158/1538-7445.AM2011-LB-412

Published: 15 April 2011

View articletitled, Abstract LB-412: Combining bexarotene with erlotinib in window of opportunity and phase II trials causes lung cancer responses independent of KRAS mutations

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 4222: N-acetyl-L-cysteine (NAC) sensitizes psammaplin A induced DNA damage in malignant hematologic cells by enhancing HDAC inhibition

Abstract 4215: Targeting TNBC with a novel vorinostat conjugate that selectively inhibits and degrades HDAC3 and HDAC6

Abstract 1829: Brusatol overcomes tyrosine kinase inhibitors resistance in myeloid leukemia cells by inhibiting translation of fast turnover protein cyclin D1 and Mcl-1

Abstract 4489: Developing dual FLT3/MNK inhibitors to overcome sorafenib resistance in FLT3-ITD AML cells

Abstract 4579: DNMT1 determines the sensitivity of Class I HDAC inhibitor Psammaplin A to induce apoptosis and DNA damage in hematological malignant cells

Abstract 5991: Improved venetoclax therapy by a novel conjugate with artemisinin by NOXA-mediated reduction of Mcl-1 and cyclin D1 protein in myeloid leukemia cells

Abstract 6055: COOTO-Me (10e) acts as a molecular glue to target NCOR/HDAC3 degradation

Abstract 31: Targeted dissociation of PF1 from SIN3A chromatin regulator complex inhibits tumor growth and metastasis in triple-negative breast cancer

Abstract 2936: Molecular characterization of the immune subclass of hepatocellualr carcinoma

Abstract 2083: Development of novel targeted adjuvant therapy for triple negative breast cancer

Abstract 4115: Inhibition of triple negative breast cancer cell invasion by the targeted interference of Sin3A function affecting Wnt and TGFβ signaling

Abstract 1989: Targeting Sin3-Pf1 complex: Novel site-specific epigenetic therapy for triple negative breast cancer

Abstract 3511: Targeted epigenetic reprogramming reverts tumor progression in triple-negative breast cancer models by the activation of retinoic acid receptor alpha

Abstract P1-12-08: Bortezomib enhances the efficacy of fulvestrant by promoting the aggregation of the ER in the cytoplasm

Abstract S6-03: Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York cancer consortium trial

Abstract 799: Diminishing Mcl-1 protein leads to apoptosis of acute myeloid leukemia cells responding to all trans retinoic acid differentiation

Abstract 807: Selamectin and ivermectin are small molecule inhibitors that interfere with Sin3A-PAH2 function and exert anti-tumor activity in triple-negative breast cancer

Abstract 411: Targeted PF1, JARID1B inhibition induces epigenetic reprogramming in triple negative breast cancer

Abstract 1826: Anti-tumorigenic effects by targeted functional disruption of the Sin3 PAH-2 domain

Abstract LB-412: Combining bexarotene with erlotinib in window of opportunity and phase II trials causes lung cancer responses independent of KRAS mutations

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only